Company Statements
YOU ARE NOW leaving interceptpharma.com
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
YOU ARE NOW leaving interceptpharma.com
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
YOU ARE NOW leaving interceptpharma.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.
Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.
For all other inquiries please contact: info@interceptpharma.com